anti-RSV
anti-RSV Brand names, anti-RSV Analogs
anti-RSV Brand Names Mixture
- No information avaliable
anti-RSV Chemical_Formula
No information avaliable
anti-RSV RX_link
http://www.rxlist.com/cgi/generic2/palivizumab.htm
anti-RSV fda sheet
anti-RSV msds (material safety sheet)
anti-RSV Synthesis Reference
sequence listed in Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997 Nov;176(5):1215-24.
anti-RSV Molecular Weight
No information avaliable
anti-RSV Melting Point
61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
anti-RSV H2O Solubility
No information avaliable
anti-RSV State
Liquid
anti-RSV LogP
No information avaliable
anti-RSV Dosage Forms
Powder for solution
anti-RSV Indication
For treatment of respiratory diseases casued by respiratory syncytial virus
anti-RSV Pharmacology
Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients.
anti-RSV Absorption
No information avaliable
anti-RSV side effects and Toxicity
No information avaliable
anti-RSV Patient Information
No information avaliable
anti-RSV Organisms Affected
No information avaliable
